Concepedia

Chad J. Swanson

CJ

Statistics

Publications

32

Citations

10.1K

H-Index

26

Active since

1994

Affiliations

Eisai (United States)(Current)

Eisai (United Kingdom)

Berry & Associates (United States)

University of Wisconsin–Madison

Lundbeck (United States)

Chad J. Swanson is an author at Eisai (United States) specializing in neuroscience, pharmacology, and neuropharmacology.

Publications per year

1994–2023

32

Publications

32

Lecanemab in Early Alzheimer’s Disease

Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 5.2K citations · Full text

, , +17

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Chad J. Swanson, Yong Zhang, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2021 · 817 citations · Full text

, , +17

The Origin and Neuronal Function of<i>In Vivo</i>Nonsynaptic Glutamate

David L. Baker, Zheng‐Xiong Xi, Hui Shen et al. · Journal of Neuroscience · 2002 · 583 citations · Full text

, , +17

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

Veronika Logovinsky, Andrew Satlin, Robert Lai et al. · Alzheimer s Research & Therapy · 2016 · 283 citations · Full text

, , +17

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Eric McDade, Jeffrey L. Cummings, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2022 · 282 citations · Full text

, , +17

1–5 of 32